CSL Executive and Leadership Team

Michelle Wightman, the Founder & Chief Executive Officer at CSL, architects the overarching corporate strategy and vision. This leadership role involves guiding the company's commitment to saving lives through advanced biotechnology, ensuring the development and delivery of critical medicines for hemophilia, immune deficiencies, and influenza vaccines. Wightman's strategic direction focuses on leveraging cutting-edge technologies to expand CSL's global reach and impact. The Founder & Chief Executive Officer ensures alignment across all business units, fostering an environment of innovation and operational excellence. This executive drives the company's long-term growth initiatives and maintains CSL's position as a leader in the biopharmaceutical sector. Michelle Wightman's influence extends to shaping the company's ethical framework and its dedication to patient well-being worldwide.

Gordon Naylor, the Interim Chief Executive Officer & Managing Director at CSL, directs daily operations and executes strategic initiatives across the global organization. This critical role ensures the seamless functioning of CSL's diverse business units, which include lifesaving medicines for hemophilia and immune deficiencies, influenza vaccines, and therapies for iron deficiency and nephrology. Naylor's leadership focuses on optimizing operational efficiency and driving market penetration in key regions. The Interim Chief Executive Officer & Managing Director oversees the integration of new technologies and the expansion of CSL's product portfolio. Gordon Naylor's responsibilities encompass fostering strong relationships with stakeholders and ensuring the company upholds its promise to save lives through the latest scientific advancements. This executive's tenure is marked by a commitment to sustained growth and operational integrity.

Ken Lim, the Chief Financial Officer at CSL, oversees all financial operations, including budgeting, forecasting, and capital allocation. This executive directs the financial strategy to support CSL's mission of saving lives with innovative biotechnology products. Lim's responsibilities include managing investor relations, ensuring compliance with financial regulations, and optimizing the company's global financial structure. The Chief Financial Officer plays a pivotal role in evaluating investment opportunities and driving profitable growth across CSL's portfolio of hemophilia treatments, immune deficiency medicines, influenza vaccines, and therapies in iron deficiency and nephrology. Ken Lim's financial acumen is essential for sustaining the company's long-term viability and its commitment to utilizing the latest technologies. This leadership position ensures financial discipline and strategic resource deployment.

Emiliano Chiaramonte, the Chief Financial Officer, LATAM (South) at CSL, directs financial strategy and operations for the South American region. This executive ensures robust financial management to support CSL's lifesaving medicines and therapies within this key market. Chiaramonte's responsibilities include optimizing regional financial performance, managing budgets, and driving investment strategies aligned with CSL's global objectives. The Chief Financial Officer, LATAM (South) plays a vital role in expanding access to treatments for hemophilia, immune deficiencies, and influenza vaccines across South America. Emiliano Chiaramonte's leadership ensures financial stability and growth, enabling CSL to fulfill its promise of using the latest technologies to save lives in the region. This role is integral to the company's international financial health and strategic expansion.

Candice Nieves, the Manager Chief Marketing Officer Quality at CSL, ensures the highest standards of quality across marketing initiatives and product communications. This role focuses on maintaining the integrity and effectiveness of CSL's marketing efforts, aligning them with the company's core promise to save lives using advanced biotechnology. Nieves's oversight guarantees that all promotional activities accurately reflect the lifesaving nature of CSL's medicines, including treatments for hemophilia, immune deficiencies, and influenza vaccines. The Manager Chief Marketing Officer Quality collaborates with various departments to implement robust quality control processes. Candice Nieves's dedication to quality supports the company's reputation and its commitment to delivering essential therapies. This position is crucial for upholding brand trust and ensuring regulatory adherence in all marketing endeavors.

Hamza Shanaa, the Manager Chief Marketing Officer Quality at CSL, implements and monitors quality assurance protocols for marketing campaigns and communications. This role is critical in upholding the integrity of CSL's brand messaging, ensuring it accurately conveys the life-saving impact of its diverse portfolio, which includes treatments for hemophilia, immune deficiencies, and influenza vaccines. Shanaa's focus is on maintaining compliance with industry standards and regulatory requirements, thereby safeguarding CSL's reputation. The Manager Chief Marketing Officer Quality collaborates with marketing teams to embed quality checks throughout the campaign lifecycle. Hamza Shanaa's commitment to excellence supports CSL's mission to save lives by ensuring that all external communications are precise and reliable. This position reinforces the company's dedication to quality in every aspect of its operations.

Ruby Eappen, the Global Quality Manager, Supplier & Chief Marketing Officer at CSL, integrates quality management principles across supplier relationships and marketing functions. This dual-focused role ensures that CSL's lifesaving medicines and therapies meet the highest quality standards, from sourcing raw materials to communicating their benefits. Eappen oversees supplier quality assurance, guaranteeing the reliability of components essential for producing treatments for hemophilia, immune deficiencies, and influenza vaccines. Simultaneously, this executive guides marketing quality, ensuring accurate and impactful communication of CSL's product value. Ruby Eappen's leadership drives continuous improvement in both supply chain integrity and marketing effectiveness, reinforcing CSL's promise to save lives using the latest technologies. This position is key to maintaining product excellence and brand trust globally.

Phyllis Post, the Vice President and Chief Information Officer, CSL Behring, Seqirus and Vifor I & T at CSL, directs the information technology strategy across multiple critical business units. This executive ensures robust, secure, and scalable IT infrastructure to support the development and delivery of lifesaving medicines and vaccines. Post's leadership focuses on leveraging technology to enhance operational efficiency, drive innovation in research and development, and improve patient access to therapies for hemophilia, immune deficiencies, and influenza. The Vice President and Chief Information Officer oversees digital transformation initiatives, data analytics, and cybersecurity measures. Phyllis Post's strategic vision enables CSL to harness the latest technologies effectively, reinforcing the company's promise to save lives. This role is fundamental to the company's global operational backbone and future technological advancements.

Amanda Taylor, the Chief Marketing Officer, Campaign & Manager (Americas) at CSL, spearheads marketing strategies and campaign execution throughout the Americas region. This executive focuses on communicating the value and impact of CSL's portfolio of lifesaving medicines, including treatments for hemophilia, immune deficiencies, and influenza vaccines. Taylor's leadership ensures that marketing efforts effectively reach healthcare providers and patients, driving awareness and access to essential therapies. The Chief Marketing Officer, Campaign & Manager (Americas) oversees regional marketing teams, developing targeted campaigns that align with CSL's global mission to save lives using advanced technologies. Amanda Taylor's strategic direction enhances CSL's market presence and reinforces its commitment to patient well-being across North and South America. This role is pivotal for regional market penetration and brand advocacy.

Henry Mezzanotte, the Executive Vice President & Head Chief Medical Officer, Research Development at CSL, leads the company's medical affairs and research and development initiatives. This executive directs the scientific strategy for discovering and advancing lifesaving medicines, focusing on areas such as hemophilia, immune deficiencies, and influenza vaccines. Mezzanotte's responsibilities include overseeing clinical trials, ensuring scientific rigor, and translating research findings into therapeutic solutions. The Executive Vice President & Head Chief Medical Officer, Research Development plays a crucial role in shaping CSL's innovation pipeline and maintaining its commitment to utilizing the latest technologies to address unmet medical needs. Henry Mezzanotte's expertise guides the development of therapies that uphold CSL's promise to save lives globally. This leadership position is central to the company's scientific advancement and product innovation.